Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) announced its earnings results on Friday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01, FiscalAI reports.
Pasithea Therapeutics Price Performance
Shares of KTTA stock traded up $0.00 during trading hours on Friday, reaching $0.52. 2,355,348 shares of the company’s stock were exchanged, compared to its average volume of 1,594,123. The company’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.61. The company has a market cap of $17.44 million, a P/E ratio of -0.33 and a beta of 0.39. Pasithea Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.06.
Wall Street Analyst Weigh In
KTTA has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, September 21st. Zacks Research downgraded Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pasithea Therapeutics presently has an average rating of “Hold” and an average price target of $3.00.
Check Out Our Latest Analysis on KTTA
About Pasithea Therapeutics
Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.
Read More
- Five stocks we like better than Pasithea Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
